Author:
Doğan Ayşegül,Demirci Selami,Telci Dilek,Canikyan Serli,Kongur Merve,Dede Bülent,Şahin Fikrettin
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics. CA Cancer J Clin 66(1):7–30
2. Chauhan A, Semwal DK, Mishra SP, Goyal S, Marathe R, Semwal RB (2016) Combination of mTOR and MAPK ınhibitors—a potential way to treat renal cell carcinoma. Med Sci 4(4):16
3. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13(3):688–696
4. MRCRC Collaborators (1999) Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353(9146):14–17
5. Van Spronsen D, De Weijer K, Mulders P, De Mulder P (2005) Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anticancer Drugs 16(7):709–717
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献